Assessing the variations in breast/ovarian cancer risk for Chinese BRCA1/2 carriers

Penetrance
DOI: 10.1101/2020.07.20.20135202 Publication Date: 2020-07-26T16:17:55Z
ABSTRACT
Abstract Background Cancer risks vary in different BRCA1/2 mutations. Previous studies based on Caucasian population have identified regions associated with elevated/reduced of breast/ovarian cancers. Since ethnic differences are known to affect mutation spectra, we interested defining Chinese-specific ovarian/breast cancer cluster (OCCR/BCCR) and comparing previously reported Caucasian-based regions. We also aim characterize the distribution estimate Chinese recurrent Methods 7,919 (3,641 unselected cancer-free women + 4,278 female patients) individuals were included study. Germline status detected amplicon-based next-generation sequencing. carriers defined as bearing likely pathogenic or calculated odds ratio (OR) breast OR ovarian cancer, their two ORs (ROR) for each region. ROR > 1 indicated elevated and/or decreasing cancer; < increasing odds. The frequency, penetrance six founder mutations respectively. Haplotype analysis age estimation performed most prevalent widely-spread BRCA1:c.5470_5477del. Results A total 729 subjects germline deleterious mutations, including 236 BRCA1 122 BRCA2 putative OCCR/BCCR partially overlapped shared structural-functional characteristics. greatly both penetrance. estimated convey low penetrance, while area-restricted seemed confer higher nearly complete BRCA1:c.5470_5477del accounting 9.5% - 18% is emerged ∼2,090 years ago (70 B.C.) during Han Dynasty, about 290 (∼14.5 generations) prior Three Kingdoms Period when a major migration occurred. Conclusion genotypes significantly risks. Hence ideally risk assessment should be mutation-specific, rather than concerning single figure. probably ancient may originated more 2,000 ago.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....